ProShare Advisors’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-11,068
| Closed | -$70.6K | – | 2040 |
|
|
2025
Q2 | $70.6K | Buy |
+11,068
| New | +$63.3K | ﹤0.01% | 1942 |
|
|
2022
Q3 | – | Sell |
-7,674
| Closed | -$239K | – | 1764 |
|
|
2022
Q2 | $239K | Sell |
7,674
-4,274
| -36% | -$146K | ﹤0.01% | 1353 |
|
|
2022
Q1 | $491K | Sell |
11,948
-1,460
| -11% | -$64.4K | ﹤0.01% | 1284 |
|
|
2021
Q4 | $583K | Buy |
13,408
+2,699
| +25% | +$122K | ﹤0.01% | 1348 |
|
|
2021
Q3 | $536K | Sell |
10,709
-7,089
| -40% | -$429K | ﹤0.01% | 1169 |
|
|
2021
Q2 | $1.12M | Buy |
17,798
+1,402
| +9% | +$90.1K | ﹤0.01% | 969 |
|
|
2021
Q1 | $1.52M | Buy |
16,396
+2,060
| +14% | +$211K | ﹤0.01% | 785 |
|
|
2020
Q4 | $1.28M | Buy |
14,336
+5,052
| +54% | +$464K | ﹤0.01% | 779 |
|
|
2020
Q3 | $959K | Buy |
9,284
+2,470
| +36% | +$266K | ﹤0.01% | 731 |
|
|
2020
Q2 | $539K | Buy |
+6,814
| New | +$508K | ﹤0.01% | 917 |
|
|
2020
Q1 | – | Sell |
-7,391
| Closed | -$399K | – | 1286 |
|
|
2019
Q4 | $399K | Buy |
7,391
+1,084
| +17% | +$58.8K | ﹤0.01% | 1179 |
|
|
2019
Q3 | $330K | Buy |
6,307
+186
| +3% | +$8.66K | ﹤0.01% | 1176 |
|
|
2019
Q2 | $296K | Sell |
6,121
-123
| -2% | -$5.89K | ﹤0.01% | 1252 |
|
|
2019
Q1 | $315K | Buy |
6,244
+193
| +3% | +$11.4K | ﹤0.01% | 1234 |
|
|
2018
Q4 | $359K | Sell |
6,051
-503
| -8% | -$32.4K | ﹤0.01% | 1063 |
|
|
2018
Q3 | $431K | Sell |
6,554
-447
| -6% | -$26.1K | ﹤0.01% | 1179 |
|
|
2018
Q2 | $353K | Buy |
7,001
+1,631
| +30% | +$85K | ﹤0.01% | 1287 |
|
|
2018
Q1 | $283K | Sell |
5,370
-673
| -11% | -$33.5K | ﹤0.01% | 1353 |
|
|
2017
Q4 | $281K | Buy |
+6,043
| New | +$254K | ﹤0.01% | 1427 |
|
|
2016
Q1 | – | Sell |
-5,173
| Closed | -$207K | – | 1610 |
|
|
2015
Q4 | $207K | Buy |
+5,173
| New | +$180K | ﹤0.01% | 1520 |
|
|
2014
Q4 | – | Sell |
-12,245
| Closed | -$261K | – | 2019 |
|
|
2014
Q3 | $261K | Sell |
12,245
-3,026
| -20% | -$69.3K | ﹤0.01% | 1810 |
|
|
2014
Q2 | $343K | Sell |
15,271
-13,105
| -46% | -$305K | ﹤0.01% | 1818 |
|
|
2014
Q1 | $717K | Buy |
+28,376
| New | +$717K | 0.01% | 1576 |
|
|
2013
Q4 | – | Sell |
-18,031
| Closed | -$343K | – | 1483 |
|
|
2013
Q3 | $343K | Buy |
18,031
+289
| +2% | +$5.16K | 0.01% | 1787 |
|
|
2013
Q2 | $256K | Buy |
+17,742
| New | +$257K | 0.01% | 1842 |
|
Other funds holding EBS
OHA
PCM
ProShare Advisors's EBS Position: Q3 2025 in Review
ProShare Advisors sold out of Emergent Biosolutions (EBS) in Q3 2025, closing a stake of 11,068 shares — an estimated $70.6K sold.
ProShare Advisors first reported a position in EBS in Q2 2013 and held it in 25 quarters. The position peaked at $1.52M in Q1 2021. 169 funds tracked by Wall St. Rank hold EBS as of Q3 2025.
- ProShare Advisors reported no remaining Emergent Biosolutions position as of Q3 2025 after selling out during the quarter.
- ProShare Advisors sold 11,068 Emergent Biosolutions shares in Q3 2025, an estimated $70.6K.
- ProShare Advisors first reported a position in Emergent Biosolutions in Q2 2013 and held it in 25 quarters.
- ProShare Advisors's Emergent Biosolutions position peaked at $1.52M in Q1 2021.
- 169 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2025.
Based on ProShare Advisors's 13F filing for Q3 2025, filed 6 Nov 2025.